Placenta
Volume 31, Issue 4 , Pages 277-281 , April 2010

Lack of Association between Unexplained Elevated Maternal Serum Alpha Fetoprotein and/or Human Chorionic Gonadotropin and the Occurrence of Placental Thrombotic Lesions

  • R. Salim

      Affiliations

    • Department of Obstetrics and Gynecology, HaEmek Medical Center, 18101 Afula, Israel
    • Rappaport Faculty of Medicine, Technion, Haifa, Israel
    • ,
  • M. Okopnik

      Affiliations

    • Department of pathology, HaEmek Medical Center, 18101 Afula, Israel
    • ,
  • G. Garmi

      Affiliations

    • Department of Obstetrics and Gynecology, HaEmek Medical Center, 18101 Afula, Israel
    • ,
  • Z. Nachum

      Affiliations

    • Department of Obstetrics and Gynecology, HaEmek Medical Center, 18101 Afula, Israel
    • Rappaport Faculty of Medicine, Technion, Haifa, Israel
    • ,
  • N. Zafran

      Affiliations

    • Department of Obstetrics and Gynecology, HaEmek Medical Center, 18101 Afula, Israel
    • ,
  • E. Shalev

      Affiliations

    • Department of Obstetrics and Gynecology, HaEmek Medical Center, 18101 Afula, Israel
    • Rappaport Faculty of Medicine, Technion, Haifa, Israel
    • Corresponding Author InformationCorresponding author at. Department of Obstetrics and Gynecology, HaEmek Medical Center, 18101 Afula, Israel. Tel.: +972 4 6494031; fax: +972 4 6494032.

,Accepted 13 January 2010.

References 

  1. Yaron Y, Cherry M, Kramer RL, O'Brien JE, Hallak M, Johnson MP, et al. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999;181:968–974
  2. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol. 2003;189:775–781
  3. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, et al. FASTER trial research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–267
  4. Caughey AB, Stotland NE, Escobar GJ. What is the best measure of maternal complications of term pregnancy: ongoing pregnancies or pregnancies delivered?. Am J Obstet Gynecol. 2003;189:1047–1052
  5. Waller DK, Lustig LS, Cunningham GC, Golbus MS, Hook EB. Second-trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death. N Engl J Med. 1991;325:6–10
  6. Hossain N, Paidas MJ. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol. 2007;31:208–212
  7. Younis JS, Samueloff A. Gestational vascular complications. Best Pract Res Clin Haematol. 2003;16:135–151
  8. Leiberman JR, Fraser D, Weitzman S, Glezerman M. Birthweight curves in southern Israel populations. Isr J Med Sci. 1993;29:198–203
  9. Mousa HA, Alfirevic1 Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?. Humanit Rep. 2000;15:1830–1833
  10. Redline RW, Ariel I, Baergen RN, Desa DJ, Kraus FT, Roberts DJ, et al. Fetal vascular obstructive lesions: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 2004;7:443–452
  11. Redline RW, Boyd T, Campbell V, Hyde S, Kaplan C, Khong TY, et al. Society for pediatric pathology, perinatal section, maternal vascular perfusion nosology committee. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 2004;7:237–249
  12. Wentworth P. The incidence and significance of intervillous thrombi in the human placenta. J Obstet Gynaecol Br Commonw. 1964;71:894–898
  13. Wilkins HL. Unexplained elevated maternal serum alpha-fetoprotein: what is the appropriate follow-up?. Curr Opin Obstet Gynecol. 1998;10:469–474
  14. Konachuk PS, Bernstein IM, Capelen EL. Uterine artery Doppler velocimetry in the detection of adverse outcomes in women with unexplained elevated maternal serum a-fetoprotein levels. Am J Obstet Gynecol. 1995;173:1115–1119
  15. American College of Obstetricians and Gynecologists . ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol. 2009;113:1405–1413
  16. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med. 1998;7:277–286
  17. Salafia CM, Silberman C, Herrerra NE, Mahoney MJ. Placental pathology at term associated with elevated midtrimester maternal serum AFP concentration. Am J Obstet Gynecol. 1988;158:1064–1066
  18. Perkes EA, Baim RS, Goodman KJ, Macri JN. Second-trimester placental changes associated with elevated maternal serum alpha-fetoprotein. Am J Obstet Gynecol. 1982;44:935–938
  19. Nelson LH, Bensen J, Burton BK. Outcomes in patients with unusually high maternal serum alpha-fetoprotein levels. Am J Obstet Gynecol. 1987;157:572–576
  20. Lieppman RE, Williams MA, Cheng EY, Resta R, Zingheim MN, Hickok DE, et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol. 1993;168:1852–1857
  21. Fox H. The effect of hypoxia on trophoblast in organ culture: a morphologic and autoradiologic study. Am J Obstet Gynecol. 1970;107:1058–1064
  22. Zhang P, Schmidt M, Cook L. Maternal vasculopathy and histologic diagnosis of preeclampsia: poor correlation of histologic changes and clinical manifestation. Am J Obstet Gynecol. 2006;194:1050–1056
  23. Fox H, Elston CW. Pathology of the placenta. In:  Bennington JL editors. The placenta in abnormalities and disorders of the fetus. London: WB Saunders; 1978;p. 248–251
  24. Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high risk pregnancies. Prenat Diagn. 1996;16:1129–1135
  25. Mikic TS, Johnson P. Second trimester maternal serum beta human chorionic gonadotrophin and pregnancy outcome. BJOG. 1999;106:598–600
  26. Huerta-Enochian G, Katz V, Erfurth S. The association of abnormal alphafetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome?. Am J Obstet Gynecol. 2001;184:1549–1553
  27. Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol. 1988;72:709–713
  28. Konachuk PS, Bernstein IM, Capelen EL. Uterine artery Doppler velocimetry in the detection of adverse outcomes in women with unexplained elevated maternal serum a-fetoprotein levels. Am J Obstet Gynecol. 1995;173:1115–1119

PII: S0143-4004(10)00036-6

doi: 10.1016/j.placenta.2010.01.010

Placenta
Volume 31, Issue 4 , Pages 277-281 , April 2010

Article Tools

* Image Usage & Resolution